EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
Klinar | News
Page 48 - Management of Advanced Urothelial Carcinoma: Emerging Therapies and Biomarkers
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
AstraZeneca Reports Results of Imfinzi and Tremelimumab in P-III DANUBE Study for Unresectable Stage IV
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial - Clinical Genitourinary Cancer
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
Continued) Key clinical trials' efficacy data of ICIs in patients with... | Download Scientific Diagram
Andrea Apolo, M.D. on Twitter: "Nice summary of ongoing phase 3 randomized #immunotherapy clinical trials in 1st line #bladdercancer #GU18 https://t.co/roifTmpolW" / Twitter
Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? - European Urology
Assessing the magnitude of reporting bias in trials of homeopathy: a cross-sectional study and meta-analysis | BMJ Evidence-Based Medicine
Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options - Cancer Treatment Reviews
Overview of Microbicide Clinical Trials | Download Table
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial - The Lancet ...
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
Management of metastatic bladder cancer - Cancer Treatment Reviews
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial - The Lancet ...
Meeting Updates Refine Approaches Toward Urothelial Carcinoma
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma - ScienceDirect
First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis - European Journal of Cancer
